Skyepharma PLC Research Update

LONDON--(Marketwire - January 21, 2009) -

                           Flutiform™ Update


LONDON, UK, 21 January 2009 -- SkyePharma PLC (LSE: SKP) today
announces that it has been notified by its partner Mundipharma that
there may be a few months' delay in the filing of the European
Marketing Authorisation Application for Flutiform™.  This is due to the
need to recruit additional patients into the on-going high dose
strength study, after some patients were assigned to the wrong study
arm in this four-armed study due to a randomisation issue.  There is no
cost implication for the additional work to SkyePharma as a result of
this.


Flutiform™ remains on track for a U.S. New Drug Application filing in
the first quarter of 2009.


For further information please contact:


SkyePharma PLC       Ken Cunningham  +44 20 7491 1777
During office hours  Peter Grant


Financial Dynamics   David Yates     +44 20 7831 3113
Outside office hours Jonathan Birt




About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops
new formulations of existing products to provide a clinical advantage
and life-cycle extension. The Company has twelve approved products in
the areas of oral, inhalation and topical delivery. The Group's
products are marketed throughout the world by leading
pharmaceutical companies. For more information, visit
www.skyepharma.com.



                    This information is provided by RNS
          The company news service from the London Stock Exchange

END